BR112023018802A2 - Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação - Google Patents

Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação

Info

Publication number
BR112023018802A2
BR112023018802A2 BR112023018802A BR112023018802A BR112023018802A2 BR 112023018802 A2 BR112023018802 A2 BR 112023018802A2 BR 112023018802 A BR112023018802 A BR 112023018802A BR 112023018802 A BR112023018802 A BR 112023018802A BR 112023018802 A2 BR112023018802 A2 BR 112023018802A2
Authority
BR
Brazil
Prior art keywords
inflammation
long
growth hormone
treatment
acting growth
Prior art date
Application number
BR112023018802A
Other languages
English (en)
Inventor
Kennett Sprogøe
Jens Kjelgaard-Hansen Mads
Elisabeth Zois Nora
Tuxen Poulsen Thomas
Yang Yang-Malten
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of BR112023018802A2 publication Critical patent/BR112023018802A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação. a presente invenção refere-se a um hormônio de crescimento de ação prolongada (gh) para uso no tratamento de uma doença induzida por inflamação.
BR112023018802A 2021-04-01 2022-03-31 Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação BR112023018802A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21166699 2021-04-01
PCT/EP2022/058584 WO2022207798A1 (en) 2021-04-01 2022-03-31 Use of long-acting growth hormone for treating inflammation-induced diseases

Publications (1)

Publication Number Publication Date
BR112023018802A2 true BR112023018802A2 (pt) 2023-10-31

Family

ID=75362497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018802A BR112023018802A2 (pt) 2021-04-01 2022-03-31 Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação

Country Status (10)

Country Link
EP (1) EP4314035A1 (pt)
JP (1) JP2024514095A (pt)
KR (1) KR20230164709A (pt)
CN (1) CN117396497A (pt)
AU (1) AU2022246997A1 (pt)
BR (1) BR112023018802A2 (pt)
CA (1) CA3212417A1 (pt)
IL (1) IL307192A (pt)
MX (1) MX2023011059A (pt)
WO (1) WO2022207798A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115845032A (zh) * 2022-10-28 2023-03-28 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
HUE045882T2 (hu) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polimer prodrug önmagát lehasító linkerrel
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
JP2010533202A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
CN101980725B (zh) 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
TW201004648A (en) 2008-05-23 2010-02-01 Enzon Pharmaceuticals Inc Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
KR101544245B1 (ko) 2009-02-03 2015-08-12 아뮤닉스 오퍼레이팅 인코포레이티드 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
AU2010277556B2 (en) 2009-07-31 2014-10-09 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
WO2011082368A2 (en) 2009-12-31 2011-07-07 Enzon Pharmaceuticals, Inc Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
US8946405B2 (en) 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports
DK2571510T3 (en) 2010-05-21 2018-11-19 Xl Protein Gmbh BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
EP2741778A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
CA2848142C (en) 2011-09-07 2021-05-18 Prolynx Llc Hydrogels with biodegradable crosslinking
SG11201501753VA (en) 2012-10-11 2015-05-28 Ascendis Pharma As Hydrogel prodrugs
WO2014060512A1 (en) 2012-10-17 2014-04-24 Novo Nordisk Health Care Ag Fatty acid acylated amino acids for growth hormone delivery
WO2016020373A1 (en) 2014-08-06 2016-02-11 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
HUE053855T2 (hu) 2014-11-18 2021-07-28 Ascendis Pharma Endocrinology Div A/S Új polimer hGH prodrogok
AR111190A1 (es) 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
JP2022502403A (ja) 2018-09-26 2022-01-11 アセンディス ファーマ エー／エス 分解性ヒアルロン酸ヒドロゲル
CN112770781A (zh) 2018-09-26 2021-05-07 阿森迪斯药物股份有限公司 新的水凝胶缀合物
BR112021020023A2 (pt) 2019-04-05 2021-12-07 Prolynx Llc Ligantes de conjugação melhorados
US20220289812A1 (en) 2019-08-09 2022-09-15 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release

Also Published As

Publication number Publication date
JP2024514095A (ja) 2024-03-28
CA3212417A1 (en) 2022-10-06
IL307192A (en) 2023-11-01
CN117396497A (zh) 2024-01-12
AU2022246997A9 (en) 2024-01-25
AU2022246997A1 (en) 2023-09-28
KR20230164709A (ko) 2023-12-04
MX2023011059A (es) 2023-09-29
WO2022207798A1 (en) 2022-10-06
EP4314035A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
BRPI0511569A (pt) composições e métodos para o tratamento de distúrbio disfórico pré-menstrual
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
CO2020013155A2 (es) Moduladores de nlrp3
GT200500028A (es) Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.
BR112023018802A2 (pt) Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
MX2021000900A (es) Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma.
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
CL2020002177A1 (es) Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas
PH12020551994A1 (en) Tlr7 agonists
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
ECSP23077322A (es) Derivados de fósforo como nuevos inhibidores de sos1
CO2022013429A2 (es) Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
MX2021014803A (es) Anticuerpo anti-factor de crecimiento de tejido conectivo y aplicacion del mismo.
CO2023009368A2 (es) Cocristal de un inhibidor de cdk
BR112018005494A2 (pt) composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença.